News coverage about Kitov Pharmaceuticals (NASDAQ:KTOV) has been trending somewhat positive recently, according to Accern Sentiment. Accern identifies positive and negative press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Kitov Pharmaceuticals earned a daily sentiment score of 0.24 on Accern’s scale. Accern also gave news stories about the company an impact score of 45.1017178636682 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Shares of Kitov Pharmaceuticals (NASDAQ KTOV) opened at $2.29 on Friday. Kitov Pharmaceuticals has a fifty-two week low of $1.27 and a fifty-two week high of $3.49.
Separately, HC Wainwright upgraded Kitov Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $10.00 price target for the company in a report on Tuesday, November 21st.
TRADEMARK VIOLATION WARNING: “Kitov Pharmaceuticals (KTOV) Earning Somewhat Favorable Press Coverage, Report Shows” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The legal version of this report can be read at https://www.dispatchtribunal.com/2018/01/12/kitov-pharmaceuticals-ktov-earns-coverage-optimism-score-of-0-24.html.
About Kitov Pharmaceuticals
Kitov Pharmaceuticals Holdings Ltd is an Israel-based company that develops non-steroidal anti-inflammatory drugs that treat pain without raising blood pressure, thus avoiding the increased risk of heart attacks, strokes or death.
Receive News & Ratings for Kitov Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kitov Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.